TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05286736

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging
Description: This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuroimaging
Description: This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative assessments
Description: Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative assessments
Description: Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function
Study: NCT05879523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1893
Description: subcutaneous, single dose, multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1893
Description: subcutaneous, single dose, multiple doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous, single dose, multiple doses
Study: NCT06399003

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine (Stamaril)
Description: This is a live, attenuated, lyophilized yellow fever vaccine manufactured by Sanofi Pasteur Europe, Lyon, France. A single dose of 0.5 mL contains with not less than 1000 IU of yellow fever virus 17D-204 strain. 0.5ml per dose.
Study: NCT05029271

Intervention type: DEVICE
Group type: OTHER
Intervention: InPen with Guardian 4 System
Description: Subjects will receive the InPen™ and InPen™ Diabetes Management App combined with the Guardian™ 4 system.
Study: NCT05048407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gynaecological laparoscopic surgery (Sirius System)
Description: The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay.
Study: NCT06472011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lean steak and potatoes
Description: Participants will be fed \~400 kcal lean steak and potatoes on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
Study: NCT06089109

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Big 3
Description: Our research team has developed an online, interactive learning management system (LMS) training. This training seeks to provide helping professionals with information and resources to identify, intervene, and prevent maternal injuries from interpersonal violence, substance use/disorder (IPV and SU/D). This training will provide healthcare professionals with the knowledge, skills, and efficacy to intervene and build capacity for prevention of maternal injuries and death due to violence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation and Effectiveness of VIP Corps Training
Description: Implement and evaluate the effectiveness of VIP Corps training aimed at students enrolled in helping professions in their last program year. intervention efficacy to change in students' knowledge, attitudes, and practices of intimate partner violence (IPV) screening, detection, and referrals; participant practices will be the primary, longer-term outcome; while changes in knowledge and attitudes will be short-term outcomes. Secondary outcomes will include changes in detecting symptoms of a) SU/D and b) depression and/or anxiety and providing appropriate resources.
Study: NCT06142643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Filler Device
Description: Injection of the device by investigators according to the IFU
Study: NCT06152614

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Delivery and Cooking PLUS Aerobic Training (FoRKS+)
Description: Food Delivery and Cooking PLUS Aerobic Training (FoRKS+) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes, and an additional 12 weeks of aerobic exercise.
Study: NCT06472011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lentil and sweet potato chili
Description: Participants will be fed \~400 kcal lentil and sweet potato chili on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: macaroni and cheese
Description: Participants will be fed \~400 kcal macaroni and cheese on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fish tacos
Description: Participants will be fed \~400 kcal fish tacos on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
Study: NCT06214936

Intervention type: OTHER
Group type: OTHER
Intervention: Benchtop Incubator
Description: half of the mature oocytes will be placed in the benchtop incubator and after ICSI the resulting inseminated oocytes and subsequent embryos will remain in the benchtop incubator for the remainder of embryo culture

Intervention type: OTHER
Group type: OTHER
Intervention: Box Incubator
Description: half of the mature oocytes will be placed in the benchtop incubator and after ICSI the resulting inseminated oocytes and subsequent embryos will remain in the box incubator for the remainder of embryo culture
Study: NCT06472011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chicken and pea fried rice
Description: Participants will be fed \~400 kcal chicken and pea fried rice on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pita and hummus
Description: Participants will be fed \~400 kcal pita and hummus on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: creamy pork pasta
Description: Participants will be fed \~400 kcal creamy pork pasta on one occasion to test for changes in blood glucose and insulin levels as well as appetite over a 4-hour period of time.
Study: NCT06647290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: Application of a negative wound pressure therapy dressing to the wound post laparotomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy
Description: Application of a negative wound pressure therapy dressing to the wound post laparotomy
Study: NCT06647329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T Therapy
Description: CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological Lymphomas
Study: NCT06646380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Training
Description: The multicomponent training (MCT) program comprised aerobic, resistance, flexibility, and balance exercises, following recommendations by Carvalho et al. (23). Sessions lasted 50 to 60 minutes, including warm-up, aerobic exercise, resistance training, balance training, and cool-down. Training intensity gradually increased over time. The experimental group will have three 60-minute sessions weekly for 32 weeks, while the control group will not participate in any exercise program, but they will maintain the daily physical activity. Both groups will be evaluated at two time points: initial assessment (M1) at the start of training and final assessment (M2) after 32 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maintenance
Description: Participants were instructed to maintain daily life activities regarding physical activity.
Study: NCT06645873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) device
Description: All included study participants recieve a CGM sensor (Dexcom G7) to monitor blood glucose. The treatment team is blind for the CGM values; the gold standard for glucose control (POC interval measures) will be followed.
Study: NCT06111339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: The placebo will be a 0.9% saline solution administered over 40 minutes.
Study: NCT04655014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Circuit Training
Description: The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
Study: NCT06645639

Intervention type: OTHER
Intervention: Pediatric Integrated Nutrition Pathway for Acute Care Pathway (P-INPAC)
Description: The pediatric working group of Canadian Malnutrition Task Force has developed an evidence-informed algorithm named the Pediatric Integrated Nutrition Pathway for Acute Care (P-INPAC). The P-INPAC outlines a process to improve nutrition care by:~1. implementing nutrition screening at point-of-admission~2. introducing standard care measures to prevent the development of malnutrition in children admitted with normal nutrition status, including standardizing the process of monitoring food intake early and systematically to identify when standard care measures are not sufficient~3. ensuring the moderately and severely malnourished patients receive timely specialized care in the form of a comprehensive assessment and treatment; and~4. ensuring moderately and severely malnourished patients receive adequate post discharge follow-up and nutrition care.~In this pilot study, we will be implementing the first two steps of P-INPAC only (screening and assessment).

Intervention type: OTHER
Intervention: Pediatric Integrated Nutrition Pathway for Acute Care Pathway (P-INPAC)
Description: The pediatric working group of Canadian Malnutrition Task Force has developed an evidence-informed algorithm named the Pediatric Integrated Nutrition Pathway for Acute Care (P-INPAC). The P-INPAC outlines a process to improve nutrition care by:~1. implementing nutrition screening at point-of-admission~2. introducing standard care measures to prevent the development of malnutrition in children admitted with normal nutrition status, including standardizing the process of monitoring food intake early and systematically to identify when standard care measures are not sufficient~3. ensuring the moderately and severely malnourished patients receive timely specialized care in the form of a comprehensive assessment and treatment; and~4. ensuring moderately and severely malnourished patients receive adequate post discharge follow-up and nutrition care.~In this pilot study, we will be implementing the first two steps of P-INPAC only (screening and assessment).
Study: NCT06125639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sauna Bathing
Description: Participants will take part in 9 evening sauna bathing session over the course of 3 weeks
Study: NCT05250622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Japanese-translated evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)
Description: Participants will receive emails with the link to Japanese-translated version of evidence summaries.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: English evidence summaries (Advanced Clinical Evidence report from OrthoEvidence)
Description: Participants will receive emails with the link to English version of evidence summaries.
Study: NCT05428514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternity Housing
Description: Receives a bed in the maternity home, wrap-around services, etc.
Study: NCT05070156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: Low-dose group
Description: 1.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
Study: NCT05608096

Intervention type: DEVICE
Intervention: Hemoperfusion
Description: Commercial membrane for extracorporeal blood purification (hemoperfusion)
Study: NCT05518383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate
Description: For patients with very limited disease (R1- stage I/II СR), the addition of rituximab might allow the omission of anthracyclines and vincristine without jeopardizing survival rates but reducing acute and long term toxicities. In this treatment arm, it is tested whether the event-free survival is similar to that of the historical control
Study: NCT06646393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin to skin contact
Description: Father-baby skin-to-skin contact was applied within the first hour immediately after the cesarean delivery. During the Father-Baby Skin-to-Skin Contact stage, the newborns were laid face down on their father's bare chest and covered with a blanket.
Study: NCT05070156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: Mid-dose group
Description: 2.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: High-dose group
Description: 3.0×105/kg positive CAR-T cells injection. 2-n doses will be evaluated by the investigator if participant is qualify for certain condition.
Study: NCT05518383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine
Description: R2: Drug: Rituximab 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine
Description: 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
Description: Rituximab 4 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, Further
Study: NCT06307184

Intervention type: PROCEDURE
Intervention: Natural proliferative phase frozen embryo transfer
Description: When endometrial thickness is above 7 mm, vaginal micronized progesterone will be administered 400mg 12/12h when the dominant follicle is at least 13 mm, serum estradiol (E2) levels are \>80 pg/ml, and serum progesterone levels are \<1.5ng/ml. Embryo transfer will be performed on the fifth day of progesterone.
Study: NCT05819996

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Environmental educational campaign
Description: Educational campaign will be conducted to promote participation in indoor air testing.
Study: NCT06272981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation
Description: THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation.
Study: NCT06499649

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IBSA Probiotics
Description: Dietary supplement base on probiotic strains.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo does not contain functional components, and the appearance is indistinguishable from the comparison product.
Study: NCT05966129

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decisions support
Description: Prescribing recommendations to the provider based on the pharmacogenetic testing results
Study: NCT05218096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet.
Study: NCT03617445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMT oral capsule
Description: FMT oral capsules, single dose of 5 capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vancomycin
Description: Oral Vancomycin 125 mg capsules every 6 hours for 14 days, followed by 125 mg oral placebo every 12 hours for 7 days, followed by 125 mg oral placebo once daily for 7 days, followed by 125 mg oral placebo every 3 days for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMT oral placebo
Description: Placebo oral capsules, single dose of 5 capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vancomycin placebo
Description: Placebo oral vancomycin capsules every 6 hours for 14 days, followed by 125 mg oral vancomycin every 12 hours for 7 days, followed by 125 mg oral vancomycin once daily for 7 days, followed by 125 mg oral vancomycin every 3 days for 14 days.
Study: NCT05896527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC-806
Description: DC-806 will be supplied as tablets to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC-806
Description: DC-806 will be supplied as tablets to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC-806
Description: DC-806 will be supplied as tablets to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC-806
Description: DC-806 will be supplied as tablets to be administered orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as tablets to be administered orally.
Study: NCT06428708

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F] PSMA-1007 PET/CT
Description: \[18F\] PSMA-1007 PET/CT scan
Study: NCT05881148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon sprinting spiked-shoes
Description: Trademarked Carbon Spiked-Shoes, from one Trademark only to ensure generalization concerns, is used alternatively with standard carbon-free spiked-shoes, for 8 repetitions of 30m-sprint each, separated by 10 minutes rest each.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard carbon-free sprinting spiked-shoes
Description: cf
Study: NCT06325579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality for Dysphagia Treatment
Description: Patients wore a VR headset while undergoing their rehabilitation session
Study: NCT04799054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon TLR7/8 Agonist
Description: TransCon TLR7/8 Agonist will be administered as an IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon TLR7/8 Agonist
Description: TransCon TLR7/8 Agonist will be administered as an IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon TLR7/8 Agonist
Description: TransCon TLR7/8 Agonist will be administered as an IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered IV
Study: NCT05325255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release of subscapularis
Description: It is the application of manual pressure over myofascial trigger point that induces ischemia and causes release of trigger points

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maitland mobilization
Description: It is the type of mobilization technique that uses passive accessory mobilization to reduce pain and stiffness and increasing range of motion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland mobilization
Description: It is the type of mobilization technique that uses passive accessory mobilization to reduce pain and stiffness and increasing range of motion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: It is the technique use to increase flexibility and range of motion of short and hypomobile structures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: It is the technique use to increase flexibility and range of motion of short and hypomobile structures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold pack
Description: It is the application of cold to provide analgesic effects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold pack
Description: It is the application of cold to provide analgesic effects
Study: NCT05529160

Intervention type: DEVICE
Intervention: FERTI LILY Conception Cup
Description: The FERTI-LILY Conception Cup is indicated for over-the-counter (OTC) home use by couples trying to conceive. The FERTI·LILY device OTC contains a cervical cap attached to a stem. The FERTI-LILY Conception Cup is intended to push semen towards the cervix as an aid in conception. It is designed to be inserted vaginally after intercourse and left in place for 20-60 minutes. The device is recommended to be used during the ovulatory phase of the menstrual cycle. It is not to be left in place for longer than six hours. The device may be re-used up to 18 times or over 6 cycles.
Study: NCT04799054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered IV
Study: NCT05922839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 160mg, orally, twice daily, for a minimum of 3 months, and for effective patients, continue to use for 2 years after achieving optimal therapeutic effect.